Month: December 2022

Posted on

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively

The Albert B. Sabin Gold Medal and Rising Star Award

The Sabin Vaccine Institute awarded R&D leader Dr. Kathrin Jansen the 2022 Gold Medal for her extraordinary contributions to vaccinology. Immunologist Dr. Kizzmekia Corbett received the 2022 Rising Star award for her work advancing the field of immunization.

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives. The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.

The Gold Medal, now in its 29th year, is Sabin’s highest scientific honor, given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege, and Myron Levine.

Dr. Jansen was selected for her nearly three decades of commitment to advancing vaccine research and development (R&D) for a range of challenging diseases from COVID-19 to HPV and pneumonia, all of which afflict adults and children in low-and middle-income countries with already fragile health care systems.

This past August, Dr. Jansen retired as the senior vice president and head of vaccine research and development at Pfizer Inc. There, Dr. Jansen led global vaccines R&D with responsibilities ranging from discovery to post-marketing commitments. In collaboration with BioNTech, Dr. Jansen spearheaded the development of a COVID-19 vaccine that would become the first FDA and WHO-authorized COVID-19 vaccine and is the first-ever approved vaccine to use an mRNA platform.

Dr. Jansen’s leadership at Pfizer also produced newer versions of a widely used pneumococcal conjugate vaccine and vaccine candidates to prevent Streptococcus pneumoniae, respiratory syncytial virus (RSV), meningococcal infections, and Group B streptococcus. Previously, she directed vaccine R&D efforts at Merck Research Laboratories and led the development of the world’s first cervical cancer vaccine. She also contributed to programs for rotavirus, mumps, measles and rubella.

“We are delighted to recognize Dr. Jansen with our Gold Medal award for her commitment to furthering vaccines and tackling tough scientific challenges in the interest of benefitting humanity and saving lives,” says Amy Finan, Sabin’s chief executive officer. “Throughout her career, she has demonstrated a unique passion for answering perplexing research questions and making bold decisions that led to impactful public health milestones.”

Dr. Jansen said she was “humbled” by the honor. “When you look at all the previous Gold Medal recipients, they are colleagues and friends that you know and have interacted and worked with for years – passionate people, all dedicated to making a healthier world.”

Sabin’s Rising Star Dr. Corbett is an assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. A viral immunologist by training, Dr. Corbett works to advance vaccine development for pandemic preparedness and to build public confidence in vaccines, particularly among communities of color facing health disparities. While at the National Institutes of Health she was a member of the team whose research on the novel coronavirus laid the groundwork for the COVID-19 Moderna vaccine – the first candidate to be tested in Phase 1 clinical trials in the U.S.

Dr. Corbett’s research has also included a universal influenza vaccine, dengue, and respiratory syncytial virus. Currently, she leads a laboratory focused on novel coronaviruses and other infectious diseases that aims to inform vaccine development against potential future pandemics. She is also a leading advocate for STEM education, health care equity, and community-based public health outreach.

“Sabin is delighted to name Dr. Corbett this year’s Rising Star,” says Finan. “Her contributions to vaccine development are matched only by her dedication to shoring up vaccine confidence, especially among skeptics. She has done incredible work explaining the scientific rigor behind vaccines and is inspiring the next generation of researchers and public health heroes.”

“It’s a really big honor for me to win this award,” says Dr. Corbett. “Having just started my career and my own lab, winning this Rising Star Award suggests that – number one – I have a long way to go but – number two – that I am capable, which is especially good to hear from my peers, mentors and other more experienced scientists.”

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world.

For more information, visit https://www.sabin.org/ and follow us on Twitter @sabinvaccine.

Media contact: Rajee Suri, rajee.suri@sabin.org

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8708580

Posted on

Kathrin Jansen, Líder de Pesquisa e Desenvolvimento de Vacinas, e Kizzmekia Corbett, Imunologista, Premiadas com as Medalhas Gold e Rising Star da Sabin, respectivamente

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — O Sabin Vaccine Institute homenageou hoje duas cientistas extraordinárias pelas suas pesquisas inovadoras sobre vacinas que mudaram o curso da pandemia da COVID-19, avançaram a saúde pública e salvaram inúmeras vidas. A Gold Medal Albert B. Sabin de 2022 foi concedida à líder de pesquisa de vacinas Kathrin U. Jansen, PhD, e a Rising Star à imunologista Kizzmekia Corbett, PhD.

A Gold Medal, agora no seu 29º ano, é a maior honra científica da Sabin, concedida anualmente a um membro distinto da comunidade de saúde global pelas suas contribuições excepcionais para o campo de vacinação ou complementar. Os vencedores dos prêmios anteriores incluem líderes de vacinação e defesa de vacinas como os Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege e Myron Levine.

A Dra. Jansen foi selecionada por suas quase três décadas de compromisso com o avanço da pesquisa e desenvolvimento de vacinas (P&D) para uma série de doenças desafiadoras, desde COVID-19 até HPV e pneumonia, que afetam adultos e crianças de países de baixa e média renda com sistemas de saúde já frágeis.

Em agosto passado, a Dra. Jansen se aposentou como vice-presidente sênior e chefe de pesquisa e desenvolvimento de vacinas da Pfizer Inc, onde liderou a pesquisa e desenvolvimento de vacinas globais com responsabilidades que vão desde a descoberta até os compromissos pós-comercialização. Em colaboração com a BioNTech, a Dra. Jansen liderou o desenvolvimento da primeira vacina em uma plataforma de mRNA contra a COVID-19 a ser autorizada pela FDA e pela OMS.

A liderança da Dra. Jansen na Pfizer também resultou em versões mais recentes de uma vacina pneumocócica conjugada amplamente usada e candidatos a vacina para prevenir o Streptococcus pneumoniae, vírus sincicial respiratório (VSR), infecções meningocócicas, e o estreptococo do Grupo B. Anteriormente, ela dirigiu os esforços de pesquisa e desenvolvimento de vacinas na Merck Research Laboratories e liderou o desenvolvimento da primeira vacina contra o câncer de colo do útero do mundo. Ela também contribuiu para programas de rotavírus, caxumba, sarampo e rubéola.

“Estamos muito contentes em conceder à Dra. Jansen o nosso prêmio Gold Medal por sua dedicação à promoção das vacinas e ao enfrentamento de desafios científicos visando beneficiar a humanidade e salvar vidas”, disse Amy Finan, diretora executiva da Sabin. “Ao longo da sua carreira, ela demonstrou um entusiasmo único por responder a perguntas de pesquisa desconcertantes e tomar decisões ousadas que levaram a marcos impactantes para a saúde pública.”

A Dra. Jansen disse que se sentiu “honrada” com a premiação. “Os ganhadores anteriores da Gold Medal são colegas e amigos com os quais eu interagi e trabalho com eles há anos – pessoas entusiasmadas, dedicadas a tornar o mundo mais saudável para todos.”

A Dra. Corbett, recebedora do prêmio Rising Star da Sabin, é professora assistente de imunologia e doenças infecciosas da Harvard T.H. Chan School of Public Health. Imunologista viral, a Dra. Corbett trabalha para promover o desenvolvimento de vacinas em antecipação às pandemias e para aumentar a confiança do público nas vacinas, particularmente entre comunidades de pessoas de cor que enfrentam disparidades de saúde. No National Institutes of Health ela foi membro da equipe cuja pesquisa sobre o novo coronavírus lançou as bases para a vacina COVID-19 Moderna – a primeira candidata a ser testada em ensaios clínicos de Fase 1 nos EUA.

A pesquisa da Dra. Corbett também incluiu uma vacina universal contra a gripe, dengue e vírus sincicial respiratório. Atualmente ela lidera um laboratório focado nos novos coronavírus e outras doenças infecciosas, visando informar o desenvolvimento de vacinas contra possíveis pandemias futuras. Ela também é uma das principais defensoras da educação STEM, da equidade nos cuidados de saúde, e do alcance da saúde pública nas comunidades.

“A Sabin tem o prazer de premiar a Dra. Corbett com o Rising Star deste ano”, disse Finan. “Sua contribuição para o desenvolvimento da vacina acompanha sua dedicação em aumentar a confiança nas vacinas, especialmente entre os céticos. Ela fez um trabalho incrível explicando o rigor científico por trás das vacinas, inspirando a próxima geração de pesquisadores e heróis da saúde pública.”

“É uma grande honra para mim ganhar este prêmio”, disse a Dra. Corbett. “O recebimento deste Prêmio Rising Star no início da minha carreira no meu próprio laboratório sugere que – primeiro – tenho um longo caminho a percorrer, mas – segundo– que sou capaz. E isso é especialmente bom de ouvir dos meus colegas, mentores e outros cientistas mais experientes.”

Sobre o Sabin Vaccine Institute

O Sabin Vaccine Institute é um dos principais defensores da expansão do acesso e uso de vacinas em todo o mundo, do avanço da pesquisa e desenvolvimento de vacinas e da ampliação do conhecimento e inovação das vacinas. Revelando o potencial das vacinas através da parceria, o Sabin criou um ecossistema robusto de financiadores, inovadores, implementadores, profissionais, formuladores de políticas e partes interessadas públicas para avançar sua visão de um futuro livre de doenças evitáveis. Como uma organização sem fins lucrativos com mais de duas décadas de experiência, o Sabin está empenhado em encontrar soluções duradouras que levem todos os benefícios das vacinas a todas as pessoas, independentemente de quem sejam ou de onde vivem. No Sabin, acreditamos no poder das vacinas para mudar o mundo.

Para mais informação, visite https://www.sabin.org/ e siga-nos no Twitter @SabinVaccine.

Contato com a Mídia: Rajee Suri, rajee.suri@sabin.org

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8709489

Posted on

La leader en recherche et développement de vaccins Kathrin Jansen et l’immunologue Kizzmekia Corbett se voient remettre respectivement la Médaille d’or et le prix Rising Star de Sabin

WASHINGTON, 07 déc. 2022 (GLOBE NEWSWIRE) — Le Sabin Vaccine Institute a récompensé aujourd’hui deux scientifiques extraordinaires pour leurs recherches de pointe en matière de vaccins qui ont permis de changer le cours de la pandémie de COVID-19, de faire progresser la santé publique et de sauver d’innombrables vies. La Médaille d’or Albert B. Sabin 2022 a été décernée à la leader de la recherche en vaccins Kathrin U. Jansen, PhD, tandis que le prix Rising Star (étoile montante) a été attribué à l’immunologue Kizzmekia Corbett, PhD.

La Médaille d’or, qui en est à sa 29e édition, est le plus prestigieux honneur scientifique de Sabin, décerné chaque année à un membre distingué de la communauté mondiale de la santé qui a apporté des contributions exceptionnelles à la vaccinologie ou à un domaine complémentaire. Les anciens lauréats incluent des chefs de file dans les domaines de la vaccinologie et de la sensibilisation aux vaccins tels que les Drs Barney Graham, Carol Baker, Anne Gershon, Bill Foege et Myron Levine.

La Dr Jansen a été sélectionnée pour ses près de 30 ans d’engagement à faire avancer la recherche et le développement (R&D) en matière de vaccins pour diverses maladies difficiles à traiter, de la COVID-19 au HPV en passant par la pneumonie, toutes susceptibles de toucher les adultes comme les enfants dans les pays à revenus faibles et modérés aux systèmes de santé déjà fragiles.

Au mois d’août passé, la Dr Jansen a quitté ses fonctions de vice-présidente sénior et de responsable de la recherche et du développement de vaccins chez Pfizer Inc. Dans cette entreprise, la Dr Jansen a mené une R&D en matière de vaccins à l’échelle mondiale, ses responsabilités allant de la découverte aux engagements post-marketing. En collaboration avec BioNTech, la Dr Jansen a été le fer de lance du développement d’un vaccin contre la COVID-19 qui est devenu le premier autorisé par la FDA et l’OMS, mais également le tout premier vaccin approuvé à utiliser une plateforme ARNm.

Le leadership de la Dr Jansen chez Pfizer a également permis de produire de nouvelles versions d’un vaccin et de candidats vaccins conjugués antipneumocoques largement utilisés dans le but de prévenir le pneumocoque, le virus respiratoire syncytial (VRS), les infections méningocoques et le streptocoque B. Elle dirigeait auparavant les initiatives de R&D en matière de vaccins chez Merck Research Laboratories et a conduit le développement du tout premier vaccin contre le cancer cervical au monde. Elle a aussi contribué à des programmes de lutte contre les rotavirus, les oreillons, la rougeole et la rubéole.

« Nous sommes ravis d’offrir la Médaille d’or à la Dr Jansen pour reconnaître son engagement à améliorer les vaccins et sa lutte face à des défis scientifiques difficiles, tout cela pour le bien de l’humanité et pour sauver des vies », a déclaré Amy Finan, présidente-directrice générale de Sabin. « Tout au long de sa carrière, elle a fait montre d’une passion exceptionnelle pour répondre aux questions de recherche les plus complexes et a pris des décisions audacieuses qui ont permis d’atteindre des étapes majeures révolutionnant la santé publique. »

La Dr Jansen a déclaré être « honorée » de recevoir ce prix. « Quand je regarde tous les précédents lauréats de la Médaille d’or, je ne vois que des collègues et amis avec qui j’ai parlé et travaillé pendant des années : des gens passionnés, voulant tous œuvrer pour un monde en meilleure santé. »

La Dr Corbett, qui a remporté le prix Rising Star de Sabin, est professeure-adjointe en immunologie et maladies contagieuses à la Harvard T.H. Chan School of Public Health. Immunologue virale de formation, la Dr Corbett œuvre dans le but de faire avancer le développement de vaccins pour préparer le monde aux pandémies et pour favoriser la confiance du public à l’égard des vaccins, particulièrement dans les communautés de couleur confrontées à des disparités en matière de santé. Quand elle travaillait aux National Institutes of Health, elle était membre de l’équipe dont les recherches sur le nouveau coronavirus ont posé les bases du vaccin Moderna contre la COVID-19, le premier candidat à avoir été testé dans des essais cliniques de phase 1 aux États-Unis.

Les recherches de la Dr Corbett s’intéressaient aussi à un vaccin universel contre la grippe, la dengue et le virus respiratoire syncytial. Elle dirige actuellement un laboratoire axé sur les nouveaux coronavirus et autres maladies contagieuses dans le but d’informer le développement de vaccins face à de futures pandémies potentielles. Elle défend aussi ardemment les études STIM, l’égalité dans les soins de santé et la sensibilisation communautaire sur la santé publique.

« Sabin se réjouit de nommer la Dr Corbett pour le prix Rising Star de cette année », a déclaré Mme Finan. « Ses contributions au développement de vaccins n’ont d’égal que son dévouement à stimuler la confiance à l’égard de ceux-ci, en particulier parmi les sceptiques. Elle a réalisé un travail incroyable pour expliquer la rigueur scientifique qui se cache derrière la conception de vaccins et inspire la nouvelle génération de chercheurs et de héros de la santé publique. »

« C’est un très grand honneur pour moi de remporter ce prix », a déclaré la Dr Corbett. « Comme je viens seulement de débuter ma carrière et de lancer mon propre laboratoire, remporter ce prix Rising Star suggère que, premièrement, j’ai encore un long chemin à parcourir mais que, deuxièmement, j’en suis capable, ce qui est particulièrement agréable à entendre de la part de mes pairs, mentors et d’autres scientifiques plus expérimentés. »

À propos du Sabin Vaccine Institute

Le Sabin Vaccine Institute est l’un des principaux défenseurs de l’élargissement de l’accès aux vaccins et de leur adoption à l’échelle mondiale, de l’avancement de la recherche et du développement de vaccins et de l’amplification des connaissances et de l’innovation en matière de vaccins. Libérant le potentiel des vaccins par le partenariat, Sabin a bâtit un écosystème robuste de bailleurs de fonds, innovateurs, agents de mise en œuvre, praticiens, décideurs politiques et parties prenantes publiques pour faire avancer sa vision d’un avenir où les maladies évitables ont enfin disparu. En tant qu’organisation sans but lucratif comptant plus de deux décennies d’expérience, Sabin s’est engagée à trouver des solutions qui durent et à étendre tous les bienfaits des vaccins à l’ensemble des individus, peu importe qui ils sont et où ils résident. Chez Sabin, nous sommes convaincus que les vaccins ont le pouvoir de changer le monde.

Pour de plus amples informations, rendez-vous sur le site https://www.sabin.org/ et suivez-nous sur Twitter @sabinvaccine.

Contact auprès des médias : Rajee Suri, rajee.suri@sabin.org

Une photo accompagnant ce communiqué de presse est disponible à l’adresse : https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8709489

Posted on

WHO: COVID-19 Sets Back Global Malaria Efforts, Especially in Africa

The COVID-19 pandemic has set global malaria control efforts back, especially in Africa, the World Health Organization says.

However, this year’s World Malaria Report says countries were able to lessen disruptions to prevention, testing and treatment.

In 2019, before the pandemic struck, there were 568,000 malaria deaths. Despite the pandemic and other humanitarian emergencies, WHO information shows concerted action by countries has prevented the worst potential impacts of COVID-19-related disruptions to malaria services.

WHO officials say the world has largely managed to salvage many of the gains made against malaria during the past 20 years.

Abdisalan Noor, head of the WHO Global Malaria Program’s Strategic Information unit, said malaria cases dramatically increased in the first year of the pandemic. However, he said the number of cases last year remained largely the same as in 2020.

“Overall, however, the pandemic and its related disruptions have led to increases in malaria burden over the last two years, and we estimate that about 63,000 deaths and about 13 million cases [were] attributed to disruptions during the COVID-19 pandemic,” he said.

Most deaths and cases have occurred in the WHO African region, Noor said, adding that progress in malaria control is continuing. For example, he said 11 countries with the world’s highest malaria levels have largely held the line against the disease during the pandemic. Among them are Burkina Faso, the Democratic Republic of Congo, India, Mali and Tanzania,

Despite the challenges posed by the pandemic, Noor said nearly 300 million insecticide-treated bed nets were distributed to susceptible families. Bed nets are regarded as the most important tool against malaria, and their declining effectiveness is of concern.

Noor cited growing insecticide resistance and households’ decreasing retention of bed nets as major problems.

“In particular, because of the physical durability of the bed net itself as well as the maintenance of the bed net in the household … we are not getting the gains we would have hoped for from the ITN [insecticide-treated net], which essentially means that given that mass campaigns have been every three years, we have a considerable period between campaigns when people are not receiving effective protection,” he said.

WHO officials consider the current setback as a temporary glitch on the road to global malaria elimination. They say key opportunities, such as a new generation of malaria control tools, could help accelerate progress toward this goal.

They say long-lasting bed nets with new insecticide combinations and other innovations in vector control are in the offing, and by late next year, the world’s first malaria vaccine will be offered to millions of children. Also, they add, other lifesaving malaria vaccines are in development.

Source: Voice of America

Posted on

WHO Urges Vigilance as COVID-19 Pandemic Wanes in Africa

The World Health Organization reports COVID-19 cases are continuing their downward spiral in Africa but warns the pandemic is not over and nations must remain vigilant.

Following a recent four-week resurgence of COVID-19, cases and deaths once again are dropping in Africa. Since this month-long spike ended on November 20, the World Health Organization has recorded slightly more than 12,300 new cases and 50 deaths.

The WHO regional director for Africa, Matshidiso Moeti, said these numbers are at their lowest levels since the start of the pandemic in 2020.

“Despite the recent uptick, there is hope that Africa will be spared the challenges of the previous two years when surging cases marred the holiday season for many,” said Moeti. “While the current efforts keep the pandemic within control, we are carefully monitoring its evolution. We must remain vigilant and be ready to adopt more stringent preventive measures if necessary.”

Moeti said investments in COVID-19 management over the last three years are paying off and the region is better able to cope with the virus. She notes the number of intensive care unit beds has increased and medical oxygen production has grown.

She said Africa also has strengthened its laboratory capacity including conducting genomic sequencing. But she added that worrisome gaps in vaccination remain, especially among the most vulnerable.

Moeti said it is urgent that health workers be vaccinated to protect them from getting severe illness and dying. Other high-risk groups who must be vaccinated, she said, include the elderly, people living with HIV, and those who have potentially life-threatening conditions such as diabetes, obesity, and cardiovascular disease.

“These, in our view, are the groups in which we need to … really push, accelerate in coverage, increasing the proportion of people that are covered and reaching the highest level of coverage possible, while also, of course, making sure that those of them who took their first series of vaccines early also are boosted so to sustain the level of immunity, particularly protect them against severe illness,” she said.

The WHO reports only 26 percent of Africans are fully vaccinated against COVID-19. Regional director Moeti said greater coverage can be achieved and more people reached by integrating COVID-19 vaccination into routine immunization and primary health care services.

As the pandemic winds down, she said, COVID-19 should be brought out of an emergency response mode and integrated into routine health care.

Source: Voice of America

Posted on

Anaqua and PatSnap Team Up to Deliver an End-to-End Pharma IP Management Solution

Integrated capabilities will enable best practices in Life Science stage gate reviews

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property management technology, today announced it is partnering with innovation intelligence platform PatSnap. The collaboration will deliver an enhanced IP management solution to provide Anaqua’s pharmaceutical industry clients with a more detailed and informed view of the market and competitive landscape for key use cases. The combined Anaqua AQX® Pharma and PatSnap Synapse solutions will help AQX Pharma clients further enhance competitiveness, keep up with the fast-paced requirements of the current market, eliminate duplicated work across functions, as well as identify and realize new areas of investment.

PatSnap is a platform for innovation intelligence, utilizing AI technology – including machine learning, computer vision and Optical Character Recognition (OCR) – that facilitates access to an unrivaled breadth of data that is connected in a meaningful way. PatSnap’s Synapse solution will give AQX Pharma users access to millions of data points, sourced utilizing best-in-class algorithms and expert manual curation, providing a comprehensive 360-degree market view and adding strategic value to drug development processes and strategy.

The new integration is in response to client requests to access more pharmaceutical market data within the AQX platform to improve internal team efficiency and streamline processes. The integration will support sharing deeper intelligence between clients and partners and simplify the route of administration through features such as docket personalization that will allow teams to focus on their most strategic initiatives. Specifically, the combined system will address the use case of conducting stage gate reviews and automatically kick off relevant workflows.

Vincent Brault, SVP of Product & Innovation at Anaqua, said, “AQX Pharma helps clients manage the business aspects of pharmaceutical IP management, while Synapse powers the external aspects of drug discovery through external and competitor drug discovery processes. Together, we’re using our unique capabilities to enable best practices in Life Science lifecycle stage gate reviews. We’re pleased to offer a complete pharma innovation solution, which can be further complemented by leveraging Anaqua’s strategic integrations, such as its innovation management solution, ideaPoint.”

Ray Chohan, Co-founder and VP of Corporate Development at PatSnap, said, “PatSnap is thrilled to team up with Anaqua, who are true innovators in life sciences IP management. Synapse will empower users of AQX Pharma to comb through millions of data points to discover and commercialize new therapies.”

Learn more about the partnership and the Anaqua AQX solution at synapse.patsnap.com/home/anaqua.

About Anaqua
Anaqua, Inc. is a premier provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software solutions, AQX® and PATTSY WAVE®, both offer best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations, tailored to each segment’s need. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide, use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, Australia, and Asia. For additional information, please visit anaqua.com, or Anaqua’s LinkedIn.

About PatSnap
PatSnap’s AI-powered innovation intelligence platform transforms billions of innovation data points into actionable intelligence for over 10,000 global customers in more than 50 countries. With an unrivaled breadth of data, including patents, drug information, technology news, market reports, scientific literature, and more, PatSnap breaks barriers to connect innovators with insights. To learn more about PatSnap, visit patsnap.com.

Company Contact:
Amanda Hollis
Director, Communications
Anaqua
617-375-2626
ahollis@Anaqua.com

GlobeNewswire Distribution ID 8709649